Back to Search Start Over

Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study

Authors :
Jeniffer Gómez-Mediavilla
Alvaro Pinto
Oliver Higuera
Mariana Díaz-Almirón
María Del Mar Muñoz
Jaime Feliu
Maite Antonio-Rebollo
Ana Custodio
Elisenda Llabrés
Beatriz Losada
Gema Soler
Regina Gironés
Laura Basterretxea
María José Molina-Garrido
Beatriz Jimenez-Munarriz
María-Dolores Torregrosa
Enrique Espinosa
Patricia Cruz
Irene Paredero
Source :
Oncologist
Publication Year :
2020
Publisher :
Oxford University Press (OUP), 2020.

Abstract

Background Standard oncology tools are inadequate to distinguish which older patients are at higher risk of developing chemotherapy-related complications. Materials and Methods Patients over 70 years of age starting new chemotherapy regimens were prospectively included in a multicenter study. A prechemotherapy assessment that included sociodemographics, tumor/treatment variables, and geriatric assessment variables was performed. Association between these factors and the development of grade 3–5 toxicity was examined by using logistic regression. Results A total of 551 patients were accrued. Chemotherapy doses (odds ratio [OR] 1.834; 95% confidence interval [CI] 1.237–2.719) and creatinine clearance (OR 0.989; 95% CI 0.981–0.997) were the only factors independently associated with toxicity. Only 19% of patients who received reduced doses of chemotherapy and had a creatinine clearance ≥40 mL/minute had grade 3–4 toxicity, compared with 38% of those who received standard doses or had a creatinine clearance Conclusion Chemotherapy doses and renal function were identified as the major risk factors for developing severe toxicity in the older patient. These factors should be considered when planning to initiate a new chemotherapy regimen and should also lead to a closer follow-up in these patients.

Details

ISSN :
1549490X and 10837159
Volume :
25
Database :
OpenAIRE
Journal :
The Oncologist
Accession number :
edsair.doi.dedup.....72cdf17a00cd5f5c5c21ab2534c778c8
Full Text :
https://doi.org/10.1634/theoncologist.2019-0701